Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
immune checkpoint inhibitor
immunotherapy
lung cancer
non-small cell lung cancer
vaccine
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
06
2022
accepted:
06
07
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shown survival benefit as a switch maintenance treatment after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). The primary objective of this trial is to establish the safety and recommended phase II dose (RP2D) of CIMAvax-EGF in combination with nivolumab as second-line therapy for NSCLC. Patients with immune checkpoint inhibitor-naive metastatic NSCLC were enrolled using a "3+3" dose-escalation design. Toxicities were graded according to CTCAE V4.03. Thirteen patients (one unevaluable), the majority with PD-L1 0%, were enrolled into two dose levels of CIMAvax-EGF. The combination was determined to be safe and tolerable. The recommended phase 2 dose of CIMAvax-EGF was 2.4 mg. Humoral response to CIMAvax-EGF was achieved earlier and in a greater number of patients with the combination compared to historical control. Four out of 12 evaluable patients had an objective response.
Sections du résumé
Background
UNASSIGNED
CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shown survival benefit as a switch maintenance treatment after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). The primary objective of this trial is to establish the safety and recommended phase II dose (RP2D) of CIMAvax-EGF in combination with nivolumab as second-line therapy for NSCLC.
Methods
UNASSIGNED
Patients with immune checkpoint inhibitor-naive metastatic NSCLC were enrolled using a "3+3" dose-escalation design. Toxicities were graded according to CTCAE V4.03. Thirteen patients (one unevaluable), the majority with PD-L1 0%, were enrolled into two dose levels of CIMAvax-EGF.
Findings
UNASSIGNED
The combination was determined to be safe and tolerable. The recommended phase 2 dose of CIMAvax-EGF was 2.4 mg. Humoral response to CIMAvax-EGF was achieved earlier and in a greater number of patients with the combination compared to historical control. Four out of 12 evaluable patients had an objective response.
Identifiants
pubmed: 35992783
doi: 10.3389/fonc.2022.958043
pmc: PMC9382666
doi:
Types de publication
Journal Article
Langues
eng
Pagination
958043Informations de copyright
Copyright © 2022 Evans, Lee, Wallace, Reid, Muhitch, Dozier, Mesa, Luaces, Santos-Morales, Groman, Cedeno, Cinquino, Fisher, Puzanov, Opyrchal, Fountzilas, Dai, Ernstoff, Attwood, Hutson, Johnson, Mazorra, Saavedra, Leon, Lage, Crombet and Dy.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2017 Dec 10;35(35):3924-3933
pubmed: 29023213
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Arch Pediatr Adolesc Med. 1998 Dec;152(12):1191-5
pubmed: 9856428
J Clin Oncol. 2021 Mar 1;39(7):723-733
pubmed: 33449799
Clin Cancer Res. 2008 Feb 1;14(3):840-6
pubmed: 18245547
J Glob Infect Dis. 2011 Jan;3(1):73-8
pubmed: 21572612
MEDICC Rev. 2007 Oct;9(1):8-10
pubmed: 21487353
J Allergy Clin Immunol. 2004 Apr;113(4):717-24
pubmed: 15100679
Nat Commun. 2020 Feb 19;11(1):948
pubmed: 32075963
Oncologist. 2019 Feb;24(Suppl 1):S31-S41
pubmed: 30819829
Transl Lung Cancer Res. 2015 Feb;4(1):36-54
pubmed: 25806345
Ann Oncol. 2003 Mar;14(3):461-6
pubmed: 12598354
Ann Oncol. 1998 Apr;9(4):431-5
pubmed: 9636835
Lung Cancer. 2013 Jan;79(1):73-6
pubmed: 23083516
Semin Oncol. 2018 Jan;45(1-2):34-40
pubmed: 30318082
J Thorac Dis. 2018 Nov;10(Suppl 33):S3994-S3998
pubmed: 30631537
Chest. 1996 Aug;110(2):367-70
pubmed: 8697835
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754
pubmed: 29654146
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
J Immunol. 2015 Mar 1;194(5):2289-99
pubmed: 25624454
Nat Med. 2019 Mar;25(3):470-476
pubmed: 30742120
Clin Transl Immunology. 2016 Dec 23;5(12):e120
pubmed: 28090322
Nat Commun. 2016 Aug 30;7:12632
pubmed: 27572267
Cancer Cell. 2019 Aug 12;36(2):168-178.e4
pubmed: 31327656
Cancer Biol Ther. 2006 Feb;5(2):145-9
pubmed: 16357522
Clin Cancer Res. 2016 Aug 1;22(15):3782-90
pubmed: 26927662
Transl Lung Cancer Res. 2018 Dec;7(6):639-646
pubmed: 30505708
Cancer Sci. 2017 May;108(5):1022-1031
pubmed: 28266140
MEDICC Rev. 2010 Winter;12(1):17-23
pubmed: 20387330